Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Cancer Ther. 2010 Sep 3;9(11):3065–3073. doi: 10.1158/1535-7163.MCT-10-0623

Figure 6.

Figure 6

Demonstration of the utility of Picchu to detect additive or competitive effects of different therapeutics. CosE37 cells were transfected to co-express Picchu-CAAX and wild type Bcr-Abl as described and Dasatinib, of the indicated concentrations, was added at 19 minutes and Imatinib was added at minute 29.